{"nct_id":"NCT03268954","title":"Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)","status":"COMPLETED","status_verified_date":"2024-10","start_date":"2017-11-28","start_date_type":"ACTUAL","primary_completion_date":"2021-05-28","primary_completion_date_type":"ACTUAL","completion_date":"2024-10-14","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["TAK"]}